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1. Introduction 
For hepatitis C, the year 1997 is characterized by 
consensus reports from France and the USA [1,2]. 
Ten years after the observation that therapy with 
a-interferon can induce biochemical remission in 
chronic active non-A, non-B hepatitis, 7 years after 
the discovery of hepatitis C virus (HCV) as the 
aetiological agent of chronic non-A, non-B hepatitis, 
there was a broadly felt need to establish consensus 
on methods for diagnosis and therapy and to explore 
the public health implication of a chronic disease 
with a prevalence of 0.2-1.2% in NW Europe and 
North America, and a rising cause of liver transplan- 
tation. 
What were the issues? In few areas of hepatology 
have findings on the sensitivity and specificity of 
diagnostic tests, and the results of intervention stud- 
ies been so homogenous as in HCV. Despite this 
solid base, opinions on strategies and management 
voiced by physicians who considered themselves 
experts have been distressingly divergent [3]. The 
key questions, listed below, were central to the con- 
sensus meetings in France and in the USA. 
. What is the natural history of hepatitis C? 
. What is the most appropriate approach to diag- 
nose and monitor patients? 
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* What recommendations can be made to patients 
to prevent transmission? 
* Which patients should be treated? 
* What is the most effective approach to therapy? 
The French report also specifically addresses the 
question of screening the general population or risk 
groups, such as recipients of blood products prior to 
1991, and past or present users of intravenous drugs. 
Remarkably, very similar consensus statements 
with clear-cut recommendations have appeared. It is 
of interest that both consensus statements were for- 
mulated by a panel of experienced scientists of vari- 
ous disciplines without expertise in hepatitis C, after 
hearing the evidence provided by a series of hepatitis 
C experts. 
In this issue of the Netherlands Journal of 
Medicine, two Dutch experts on hepatitis C review 
the progress on chronic hepatitis C virus disease in 
the last 5 years [4]. There are several discrepancies 
between the consensus reports and the Dutch review. 
2. The natural history of hepatitis C 
The statement in the Dutch review article that “of 
those infected probably 60% and perhaps up to 90% 
develop chronic infection resulting in cirrhosis in 
20-50% after a mean duration of about 20 years” 
may be not so much different from the statement in 
the American Report, which mentions development 
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of cirrhosis in at least 20% within two decades ot 
onset of infection. However, the American report. 
mitigating this statement, also reads “chronic hepati- 
tis C is typically an insidious process, progressing, if 
at all, at a slow rate without symptoms or physical 
signs in the majority of patients during the first two 
decades after infection’ ’ . In contrast, the Dutch re- 
view article underlines their original statement with 
the comment that the rate of progression to cirrhosis 
is diverging and may take less than 5 years, thereby 
stressing the severity of the disease. Much of the 
uncertainty of the natural history of chronic hepatitis 
C has been solved by a French retrospective study in 
2235 patients [5]. Three independent factors associ- 
ated with progressive liver disease were identified: 
age of more than 40 years at the time of infection; 
daily use of 50 g alcohol or more; and male gender. 
The group of cirrhosis within 30 years (33% of the 
total group), was characterized by males and con- 
sumers of alcohol; the group unlikely to develop 
cirrhosis in 50 years (30% of the total group), was 
predominantly women, infected at a young age and 
abstainers from alcohol. 
3. The diagnosis of hepatitis C 
The paragraph on ELISA methods in the Dutch 
review suggests both false-positive and false-nega- 
tive results in a clinically relevant number of pa- 
tients, in contrast to the French and the American 
texts stating that scientific and medico-economic data 
allow, without hesitation, the practice of testing for 
HCV by a single EIA test (second or third genera- 
tion) in the majority of individuals. For low-risk 
individuals, such as blood donors, a negative EIA is 
sufficient to rule out infection. In patients presenting 
with liver disease, a positive EIA test is sufficient to 
diagnose hepatitis C infection; a qualitative HCV 
RNA test can be used for confirmation. Low risk 
individuals with a positive EIA test should undergo 
supplemental testing. The practice of confirming pos- 
itive results by RIBA has now become a matter of 
debate; confirmation can also be made by anti-HCV 
testing in a second blood sample, supplemented by 
HCV RNA testing, if indicated, and if reliable labo- 
ratory facilities are accessible. 
4. Recommendations to prevent transmission 
Both consensus reports mention the very low risk 
of sexual transmission (the Dutch review mentions 
6-250/c) and advise no special measures for stable 
relationships except in the case of genital lesions or 
menstruation. For individuals with multiple sexual 
partners, safe-sexual practices, including the use of 
latex condoms, are strongly encouraged as a general 
approach of avoiding disease transmission. 
5. Indications for interferon therapy 
The Dutch review recommends antiviral therapy 
for all individuals with detectable HCV RNA and a 
liver biopsy showing chronic hepatitis (see Fig. 1 in 
review). 
The consensus reports do not recommend antiviral 
therapy for individuals with normal ALT (about 30% 
of the index population) nor for patients with cirrho- 
sis (about 20%). Only patients with chronic hepatitis, 
elevated ALT and histologically at least moderate 
lobular or piecemeal necrosis are candidates for ther- 
apy. 
6. Most effective approach to therapy 
The standard intention-to-treat regimen is 3 mil- 
lion units of a-interferon thrice weekly for 12 
months. However, patients without ALT normalisa- 
tion after 3 months (about 40%) or those with initial 
ALT normalisation, but ‘breakthrough’ (about 25%), 
have virtually no chance of a sustained response and 
should discontinue interferon therapy, according to 
the consensus reports. The Dutch review mentions 
several options, but is less specific with regard to the 
standard approach anno 1997. 
7. Discussion 
Developments in the management of viral dis- 
eases are rapid. Dutch investigators have contributed 
and are still contributing substantially to this exciting 
field. In this setting, it is only natural and even 
essential that experts explore different approaches in 
their clinical research. When it comes to updating the 
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medical profession, balanced guidelines formulated 
by experienced scientists not directly involved in the 
field, like the French and American consensus re- 
ports, may be preferable to the personal opinions of 
experts in the field, in view of the divergent results 
registered by an epidemiological survey [3]. 
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